Tag: certolizumab pegol
CIMZIA effective in treating axial spondyloarthritis patients
CIMZIA (certolizumab pegol) is the first therapy to demonstrate positive results in a 52-week, placebo controlled non-radiographic axial spondyloarthritis study. The positive topline results...